Alnylam Pharmaceuticals (ALNY) Shares Outstanding (2009 - 2026)

Alnylam Pharmaceuticals (ALNY) has 18 years of Shares Outstanding data on file, last reported at $133.4 million in Q1 2026.

• For the quarter ending Q1 2026, Shares Outstanding rose 2.4% year-over-year to $133.4 million; the trailing twelve-month figure through Mar 2026 stood at $133.4 million (up 2.4% YoY), and the FY2025 full-year result was $132.4 million, up 2.38% from the prior year.
• Shares Outstanding for Q1 2026 stood at $133.4 million, up from $132.4 million in the prior quarter.
• Across five years, Shares Outstanding topped out at $133.4 million in Q1 2026 and bottomed at $120.7 million in Q1 2022.
• The 5-year median for Shares Outstanding is $126.5 million (2024), against an average of $127.1 million.
• Peak annual rise in Shares Outstanding reached 3.23% in 2023, while the deepest fall reached 1.51% in 2023.
• A 5-year view of Shares Outstanding shows it stood at $123.9 million in 2022, then gained by 1.51% to $125.8 million in 2023, then grew by 2.78% to $129.3 million in 2024, then increased by 2.38% to $132.4 million in 2025, then rose by 0.81% to $133.4 million in 2026.
• The last three Shares Outstanding figures came in at $133.4 million (Q1 2026), $132.4 million (Q4 2025), and $131.8 million (Q3 2025), per Business Quant data.

Peer Comparison